Poor correlation between preclinical and patient efficacy data for tumor targeted monotherapies in glioblastoma: the results of a systematic review

[1]  A. Balasubramanian,et al.  Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma , 2020, Neuro-oncology advances.

[2]  G. Reifenberger,et al.  EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood , 2020, Nature Reviews Clinical Oncology.

[3]  Raymond Y Huang,et al.  Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. , 2020, Neuro-oncology.

[4]  J. Nieva,et al.  A Systematic Review of the Efficacy of Preclinical Models of Lung Cancer Drugs , 2020, Frontiers in Oncology.

[5]  M. J. van den Bent,et al.  INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma , 2019, Neuro-oncology.

[6]  M. Ahluwalia,et al.  Phase II study of Dovitinib in recurrent glioblastoma , 2019, Journal of Neuro-Oncology.

[7]  T. Cloughesy,et al.  Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody–drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII , 2019, Cancer Chemotherapy and Pharmacology.

[8]  Peng-fei Wang,et al.  Bioactivity and safety of chimeric switch receptor T cells in glioblastoma patients. , 2019, Frontiers in bioscience.

[9]  H. Fine,et al.  Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma , 2019, Journal of immunotherapy.

[10]  Giles W. Robinson,et al.  Challenges to curing primary brain tumours , 2019, Nature Reviews Clinical Oncology.

[11]  J. Tolson,et al.  A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098 , 2018, Neuro-oncology.

[12]  Tao Jiang,et al.  Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor , 2018, Cell.

[13]  Hao Xiong,et al.  Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study , 2017, Cancer Chemotherapy and Pharmacology.

[14]  O. Larsson,et al.  Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response , 2017, Oncotarget.

[15]  R. Grossman,et al.  HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial , 2017, JAMA oncology.

[16]  K. Mansfield,et al.  A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma , 2017, Science Translational Medicine.

[17]  Pieter Wesseling,et al.  Glioma: experimental models and reality , 2017, Acta Neuropathologica.

[18]  P. Wen,et al.  Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-&bgr; tyrosine kinase inhibitor, in patients with recurrent glioblastoma , 2016, Neuro-oncology.

[19]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[20]  R. Fimmers,et al.  Phase I trial of dovitinib (TKI258) in recurrent glioblastoma , 2016, Journal of Cancer Research and Clinical Oncology.

[21]  Jill S Barnholtz-Sloan,et al.  Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution , 2015, Genome research.

[22]  Shawn M. Gillespie,et al.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma , 2014, Science.

[23]  Claes Wohlin,et al.  Guidelines for snowballing in systematic literature studies and a replication in software engineering , 2014, EASE '14.

[24]  T. Mikkelsen,et al.  Phase I Study of GRN1005 in Recurrent Malignant Glioma , 2013, Clinical Cancer Research.

[25]  E S Sena,et al.  Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted? , 2013, British Journal of Cancer.

[26]  H. Fine,et al.  A phase I/II trial of vandetanib for patients with recurrent malignant glioma. , 2012, Neuro-oncology.

[27]  Rolf Bjerkvig,et al.  In vivo models of primary brain tumors: pitfalls and perspectives , 2012, Neuro-oncology.

[28]  K. Aldape,et al.  Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients , 2012, Cancer Chemotherapy and Pharmacology.

[29]  S. Pannullo,et al.  Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma. , 2012, Journal of experimental therapeutics & oncology.

[30]  P. Wen,et al.  Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial , 2012, Cancer Chemotherapy and Pharmacology.

[31]  S. Phuphanich,et al.  Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. , 2011, Neuro-oncology.

[32]  Thomas C. Chen,et al.  A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas , 2011, Cancer.

[33]  T. Mikkelsen,et al.  Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas , 2011, Journal of Neuro-Oncology.

[34]  Susan M. Chang,et al.  A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. , 2011, Neuro-oncology.

[35]  J. Olson,et al.  Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma , 2010, Journal of Neuro-Oncology.

[36]  W. Mason,et al.  Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  H. Fine,et al.  A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. , 2010, Neuro-oncology.

[38]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[39]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[40]  M. J. van den Bent,et al.  Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Suzanne Kamel-Reid,et al.  A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation , 2009, Cancer Chemotherapy and Pharmacology.

[42]  T. Mikkelsen,et al.  Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Denis Lacombe,et al.  Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  J. Olson,et al.  Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. , 2008, Neuro-oncology.

[45]  S. Horvath,et al.  Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma , 2008, PLoS medicine.

[46]  T. Mikkelsen,et al.  Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Howard A. Fine,et al.  Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 , 2006, Clinical Cancer Research.

[48]  Susan Chang,et al.  Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. , 2006, Neuro-oncology.